| Autor: |
Chiemi, Ono, Mitsue, Yamagami, Rika, Kamatani, Makoto, Yamamoto, Tomoya, Mukouyama, Masakazu, Sugimoto, Taizan, Suzuki, Nobuyuki, Kamo, Nobuhiko, Seki, Kenji, Eguchi, Tadashi, Ikeda |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Gan to kagaku ryoho. Cancerchemotherapy. 39(5) |
| ISSN: |
0385-0684 |
| Popis: |
Epirubicin hydrochloride(EPI)is well known to cause phlebitis as a typical adverse drug reaction. By preventing the development of severe phlebitis, patients are expected to continue effective chemotherapy with EPI without a decrease in QOL. We have previously reported promising results of a new injection method to prevent phlebitis from occurring during EPI therapy thorough a prospective clinical trial in our hospital(Jpn J Cancer Chemother 36: 969-974, 2009). In the present study, we have compared the conventional injection method(EPI main -route method, n=15)with our new method, which has been consistently practiced at present(EPI sub -route method, n=77). We found that in the EPI main -route method, angialgia/phlebitis developed in 14 of 15 cases(Grade 3, 53. 3%), leading to alteration of the regimen in 3 cases. On the other hand, with the EPI sub -route method, incidence of angialgia/phlebitis was markedly decreased, and only 6 of 77 cases developed these adverse reactions(Grade 3, 0%). One possible explanation for these results is that the reduction of intimal stimulation by the EPI sub -route method might be caused by the dilution and washout of EPI with pre-medication, as well as the shortened infusion times of EPI. Therefore, on the basis of the above hypothesis, we conclude that the EPI sub-route method might be a more effective treatment for the expected prevention of angialgia/phlebitis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
